Table 2 Association of CD44 and CD24 with clinicopathological variables in 69 SGMN patients
From: CD44/CD24 immunophenotypes on clinicopathologic features of salivary glands malignant neoplasms
CD44 | CD24 | ||||||
|---|---|---|---|---|---|---|---|
+ | - | p | + | - | p | ||
Gender | Male | 19 (13.0%) | 9 (13.0%) | 0.330 | 6 (8.7%) | 22 (31.9%) | 0.330 |
Female | 31 (44.9%) | 10 (14.5%) | 12 (17.4%) | 29 (42.0%) | |||
Age | ≤ 60 | 30 (43.5%) | 11 (15.9%) | 0.543 | 10 (14.5%) | 31 (44.9%) | 0.453 |
> 60 | 20 (29.0%) | 8 (11.6%) | 8 (11.6%) | 20 (29.0%) | |||
Smoking intake | Yes | 15 (21.7%) | 8 (11.6%) | 0.250 | 5 (7.2%) | 18 (26.1%) | 0.392 |
No | 35 (50.7%) | 11 (15.9%) | 13 (18.8%) | 33 (47.8%) | |||
Alcohol intake | Yes | 9 (13.0%) | 5 (7.2%) | 0.324 | 5 (7.2%) | 9 (13.0%) | 0.275 |
No | 41 (59.4%) | 14 (20.3%) | 13 (18.8%) | 42 (60.9%) | |||
PLSa | Majorb | 34 (49.3%) | 8 (11.6%) | 0.046 | 11 (15.9%) | 31 (44.9%) | 0.605 |
Minorc | 16 (23.2%) | 11 (15.9%) | 7 (10.1%) | 20 (29.0%) | |||
Tumor size | T1/T2 | 28 (40.6%) | 14 (20.3%) | 0.142 | 7 (10.1%) | 35 (50.7%) | 0.027 |
T3/T4 | 22 (31.9%) | 5 (7.2%) | 11 (15.9%) | 16 (23.2%) | |||
Clinical Stage | I / II | 19 (27.5%) | 6 (8.7%) | 0.419 | 2 (2.9%) | 23 (33.3%) | 0.008 |
III / VI | 31 (44.9%) | 13 (18.8%) | 16 (23.2%) | 28 (40.6%) | |||
Treatment | Surgery | 14 (20.3%) | 5 (7.2%) | 0.572 | 4 (5.8%) | 15 (21.7%) | 0.398 |
Sur. Adj. T.d | 36 (52.2%) | 14 (20.3%) | 14 (20.3%) | 36 (52.2%) | |||
Metastasis | No | 32 (46.4%) | 11 (15.9%) | 0.421 | 10 (14.5%) | 33 (47.8%) | 0.339 |
Yes | 18 (26.1%) | 8 (11.6%) | 8 (11.6%) | 18 (26.1%) | |||
loco-regional | No | 33 (47.8%) | 12 (17.4%) | 0.519 | 10 (14.5%) | 35 (50.7%) | 0.236 |
recurrence | Yes | 17 (24.6%) | 7 (10.1%) | 8 (11.6%) | 16 (23.2%) | ||
Lymph node | Negative | 43 (62.3%) | 15 (21.7%) | 0.352 | 10 (14.5%) | 48 (69.6%) | 0.001 |
Positive | 7 (10.1%) | 4 (5.8%) | 8 (11.6%) | 3 (4.3%) | |||
Death | No | 36 (52.2%) | 12 (17.4%) | 0.332 | 14 (20.3%) | 34 (49.3%) | 0.285 |
Yes | 14 (20.3%) | 7 (10.1%) | 4 (5.8%) | 17 (24.6%) | |||
CD24 | Negative | 36 (52.2%) | 15 (21.7%) | 0.398 | |||
Positive | 14 (20.3%) | 4 (5.8%) | |||||
CD44 | Negative | 4 (5.8%) | 15 (21.7%) | 0.398 | |||
Positive | 14 (20.3%) | 36 (52.2%) | |||||